These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39177646)

  • 1. Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian.
    Au-Yeung G; MacArthur E; Chan J; Ilenkovan N; Frumovitz M; Fader AN; Gourley C
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431818. PubMed ID: 39177646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
    Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
    Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BRAF pathway in low-grade serous ovarian cancer.
    Perrone C; Angioli R; Luvero D; Giannini A; Di Donato V; Cuccu I; Muzii L; Raspagliesi F; Bogani G
    J Gynecol Oncol; 2024 Jul; 35(4):e104. PubMed ID: 38768941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular changes driving low-grade serous ovarian cancer and implications for treatment.
    Kelliher L; Yoeli-Bik R; Schweizer L; Lengyel E
    Int J Gynecol Cancer; 2024 Oct; 34(10):1630-1638. PubMed ID: 38950921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in precision therapy of low-grade serous ovarian cancer: A review.
    Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
    Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis.
    Gibbs J; Mei S; Economos K; Lee YC; Kanis MJ
    Am J Obstet Gynecol; 2019 Jul; 221(1):53.e1-53.e6. PubMed ID: 30849352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
    J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-grade serous ovarian cancer: A review.
    Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
    Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The highs and lows of serous ovarian cancer.
    Grisham RN; Manning-Geist BL; Chui MH
    Cancer; 2023 Sep; 129(17):2613-2620. PubMed ID: 37366225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
    McNamara B; Demirkiran C; Hartwich TMP; Bellone S; Manavella D; Mutlu L; Greenman M; Zipponi M; Yang-Hartwich Y; Yang K; Ratner E; Schwartz PE; Coma S; Pachter JA; Santin AD
    Gynecol Oncol; 2024 Apr; 183():133-140. PubMed ID: 38493021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
    Angarita AM; Cholakian D; Fader AN
    Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
    Grisham RN; Chui MH
    Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
    Zwimpfer TA; Tal O; Geissler F; Coelho R; Rimmer N; Jacob F; Heinzelmann-Schwarz V
    Cancer Treat Rev; 2023 Jan; 112():102497. PubMed ID: 36525716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutics in low-grade serous ovarian cancer.
    Cobb L; Gershenson D
    Int J Gynecol Cancer; 2023 Mar; 33(3):377-384. PubMed ID: 36878564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
    Voutsadakis IA
    Int J Gynecol Cancer; 2020 Oct; 30(10):1619-1626. PubMed ID: 31780569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
    Hollis RL; Elliott R; Dawson JC; Ilenkovan N; Matthews RM; Stillie LJ; Oswald AJ; Kim H; Llaurado Fernandez M; Churchman M; Porter JM; Roxburgh P; Unciti-Broceta A; Gershenson DM; Herrington CS; Carey MS; Carragher NO; Gourley C
    Gynecol Oncol; 2024 Jul; 186():42-52. PubMed ID: 38582027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-grade serous carcinoma: new concepts and emerging therapies.
    Romero I; Sun CC; Wong KK; Bast RC; Gershenson DM
    Gynecol Oncol; 2013 Sep; 130(3):660-6. PubMed ID: 23707670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.